Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa, thereby inhibiting thrombus formation and propagation.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous: Initial bolus 80 units/kg, then continuous infusion 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
30-150 minutes (dose-dependent, nonlinear); at therapeutic doses ~60-90 minutes; prolonged in hepatic/renal impairment.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Primarily renal (40-60% as unchanged drug); minor biliary/fecal (<10%).
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte